Prot #UMCC 2017.026NU UM17I01: A Multi-Center Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer

Project: Research project

StatusActive
Effective start/end date10/12/187/24/27

Funding

  • University of Michigan (Prot #UMCC 2017.026NU UM17I01)
  • Bristol-Myers Squibb Company (Prot #UMCC 2017.026NU UM17I01)